Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic basis for clinical response to CTLA-4 blockade in melanoma.

The New England journal of medicine - 4 Dec 2014

Snyder Alexandra, Makarov Vladimir, Merghoub Taha, Yuan Jianda, Zaretsky Jesse M, Desrichard Alexis, Walsh Logan A, Postow Michael A, Wong Phillip, Ho Teresa S, Hollmann Travis J, Bruggeman Cameron, Kannan Kasthuri, Li Yanyun, Elipenahli Ceyhan, Liu Cailian, Harbison Christopher T, Wang Lisu, Ribas Antoni, Wolchok Jedd D, Chan Timothy A

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti-CTLA-4 treatment prolongs overall survival in patients with melanoma. CTLA-4 blockade activates T cells and enables them to destroy tumor cells. METHODS: We obtained tumor tissue from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CTLA-4 Antigen

Share to Histocompatibility Testing

Share to Ipilimumab

Share to Melanoma

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 25409260
DOI: 10.1056/NEJMoa1406498
PMCID: PMC4315319

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic basis for clinical response to CTLA-4 blockade in melanoma.PMID 25409260Read ↗

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.Semantic proximity Read ↗

Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade.Semantic proximity Read ↗

Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 BlockadeSemantic proximity Read ↗

Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance MechanismsSemantic proximity Read ↗

Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanomaSemantic proximity Read ↗

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Semantic proximity Read ↗

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.Semantic proximity Read ↗

Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers.Semantic proximity Read ↗

HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.Semantic proximity Read ↗

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.Semantic proximity Read ↗

Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response RatesSemantic proximity Read ↗

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.